Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy

NCT00050011 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

602

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms
Osteoporosis

Interventions

DRUG: Zoledronic Acid
DRUG: Letrozole

Sponsor

Novartis Pharmaceuticals